A new amoxicillin/clavulanate therapeutic system: Preparation, in vitro and pharmacokinetic evaluation

International Journal of Pharmaceutics

Volumn 335, Issue 1-2, 2007, Pages 106-113

  Kerč, Janez ^a   Opara, Jerneja ^a  

^a Lek dd   (Slovenia)

Author keywords

Amoxicillin; Clavulanate; Floating capsule; In vitro study; Pharmacokinetic study; Therapeutic system

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CLAVULANIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG RELEASE; DRUG SYNTHESIS; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIA; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; REFERENCE VALUES; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; THERAPEUTIC EQUIVALENCY;

EID: 33947592767     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.11.007     Document Type: Article

References (47)

1. Alvisi V., Gasparetto A., Dentale A., Heras H., Felletti-Spadazzi A., and D'Ambrosi A. Bioavailability of a controlled release formulation of ursodeoxycholic acid in man. Drugs Exp. Clin. Res. 22 (1996) 29-33
2. Andes D.A., and Craig W.A. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42 (1998) 2375-2379
3. Andes D., and Craig W.A. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 19 (2002) 261-268
4. Barr W.H., Zola E.M., Candler E.L., Hwang S.M., Tendolkar A.V., Shamburek R., Parker B., and Hilty M.D. Differential absorption of amoxicillin from the human small and large intestine. Clin. Pharmacol. Ther. 56 (1994) 279-285
5. Bechgaard H., and Ladefoged K. Distribution of pellets in the gastrointestinal tract. The influence on transit time exerted by the density or diameter of pellets. J. Pharm. Pharmacol. 30 (1978) 690-692
6. Bronner S., Pompei D., Elkhaili H., Dhoyen N., Monteil H., and Jehl F. Ex vivo 12 h bactericidal activity of oral co-amoxiclav (1.125 g) against beta-lactamase-producing Haemophilus influenzae. J. Antimicrob. Chemother. 48 (2001) 501-506
7. Caldwell, L.J., Gardner, C.R., Cargill, R.C., 1988a. Drug delivery device which can be retained in the stomach for a controlled period of time. US Patent 4,735,804 (5 April).
8. Caldwell, L.J., Gardner, C.R., Cargill, R.C., Higuchi, T., 1988b. Drug delivery device which can be retained in the stomach for a controlled period of time, US Patent 4,758,436 (19 July).
9. Caldwell, L.J., Gardner, C.R., Cargill, R.C., 1988c. Drug delivery device which can be retained in the stomach for a controlled period of time. US Patent 4,767,627 (30 August).
10. Cargill R., Caldwell L.J., Engle K., Fix J.A., Porter P.A., and Gardner C.R. Controlled gastric emptying. I. Effects of physical properties on gastric residence times of nondisintegrating geometric shapes in beagle dogs. Pharm. Res. 5 (1988) 533-536
11. Chulavatnatol S., and Charles B.G. Determination of dose-dependent absorption of amoxycillin from urinary excretion data in healthy subjects. Br. J. Clin. Pharmacol. 38 (1994) 274-277
12. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26 (1998) 1-12
13. Dagan R., Klugman K.P., Craig W.A., and Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J. Antimicrob. Chemother. 47 (2001) 129-140
14. Davis S.S., Stockwell A.F., Taylor M.J., Hardy J.G., Whalley D.R., Wilson C.G., Bechgaard H., and Christensen F.N. The effect of density on the gastric emptying of single- and multiple-unit dosage forms. Pharm. Res. 3 (1986) 208-213
15. DeRyke C.A., Lee S.Y., Kuti J.L., and Nicolau D.P. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles. Impact on the development of resistance. Drugs 66 (2006) 1-14
16. Deshpande A.A., Shah N.H., Rhodes C.T., and Malick W. Development of a novel controlled-release system for gastric retention. Pharm. Res. 14 (1997) 815-819
17. Dollery C.T. Therapeutic Drugs. 2nd ed. (1999), Churchill Livinstone, London pp. A162-A165
18. Dollery C.T. Therapeutic Drugs. 2nd ed. (1999), Churchill Livinstone, London pp. C253-C256
19. File T.M., Garau J., Jacobs M.R., Wynne B., Twynholm M., and Berkowitz E. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains. Int. J. Antimicrob. Agents 25 (2005) 110-119
20. Fix J.A., Cargill R., and Engle K. Controlled gastric emptying. III. Gastric residence time of a nondisintegrating geometric shape in human volunteers. Pharm. Res. 10 (1993) 1087-1089
21. Frimodt-Moller N. How predictive is PK/PD for antibacterial agents?. Int. J. Antimicrob. Agents 19 (2002) 333-339
22. Gröning R., and Heun G. Oral dosage forms with controlled gastrointestinal transit. Drug Dev. Ind. Pharm. 10 (1984) 527-539
23. Gröning R., and Heun G. Dosage forms with controlled gastrointestinal passage-studies on the absorption of nitrofurantoin. Int. J. Pharm. 56 (1989) 111-116
24. Kedzierewicz F., Thouvenot P., Lemut J., Etienne A., Hoffman M., and Maincent P. Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy. J. Control. Release 58 (1999) 195-205
25. Lehr C.M. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Syst. 11 (1994) 119-160
26. Lenaerts V.M., and Gurny R. Bioadhesive Drug Delivery Systems (1990), CRC Press, Boca Raton, FL
27. Leung S.H., Irons B.K., and Robinson J.R. Polyanionic hydrogel as a gastric retention system. J. Biomater. Sci. Polym. Ed. 4 (1993) 483-492
28. Mamajek, R.C., Moyer, E.S., 1980. Drug-dispensing device and method. US Patent 4,207,890 (17 June).
29. Note for Guidance on the Investigation of Bioavailability and Bioequivalence, January 2002. EMEA, CPMP/EWP/QWP/1401/98.
30. Paintaud G., Alvan G., Dahl M.L., Grahnen A., Sjovall J., and Svensson J.O. Nonlinearity of amoxicillin absorption kinetics in human. Eur. J. Clin. Pharmacol. 43 (1992) 283-288
31. Piotrovskij V.K., Paintaud G., Alvan G., and Trnovec T. Modelling of the saturable time-constrained amoxicillin absorption in humans. Pharm. Res. 11 (1994) 1346-1351
32. Ponchel G., and Irache J.M. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev. 34 (1998) 191-219
33. Rednick, A.B., Tucker, S.J., 1970. Sustained release bolus for animal husbandry, US Patent 3,507,952 (21 April).
34. Russell J., and Bass P. Canine gastric emptying of polycarbophil: an indigestible, particulate substance. Gastroenterology 89 (1985) 307-312
35. Russell J., and Bass P. Canine gastric emptying of fiber meals: influence of meal viscosity and antroduodenal motility. Am. J. Physiol. 249 (1985) G662-G667
36. Singh B.N., and Kim K.H. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J. Control. Release 63 (2000) 235-259
37. ® tablet and rationale for twice-daily dosing regimen. Int. J. Clin. Pharmacol. Ther. 42 (2004) 165-173
38. Thorburn C.E., Molesworth S.J., Sutherland R., and Rittenhouse S. Postantibiotic and post-beta-lactamase inhibitor effects of amoxicillin plus clavulanate. Antimicrob. Agents Chemother. 40 (1996) 2796-2801
39. Todd P.A., and Benfield P. Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 39 (1990) 264-307
40. Torres-Molina F., Peris-Ribera J.E., Garcia-Carboneli M.C., Aristorena J.C., and Pla-Delfina M.J. Nonlinearities in amoxycillin pharmacokinetics II absorption studies in the rat. Biopharm. Drug Dispos. 13 (1992) 39-53
41. Urquhart, J., Theeuwes, F., 1984. Drug delivery system comprising a reservoir containing a plurality of tiny pills. US Patent 4,434,153 (28 February).
42. Vree T.B., Dammers E., and Exler P.S. Identical pattern of highly variable absorption of clavulanic acid from four different oral formulations of co-amoxiclav in healthy subjects. J. Antimicrob. Chemother. 51 (2003) 373-378
43. Westphal J.F., Deslandes A., Brogard J.M., and Carbon C. Reappraisal of amoxicillin absorption kinetics. J. Antimicrob. Chemother. 27 (1991) 647-654
44. White A.R., Kaye C., Poupard J., Pypstra R., Woodnutt G., and Wynne B. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J. Antimicrob. Chemother. 53 (2004) i3-i20
45. Wilson C.G., and Washington N. The stomach: its role in oral drug delivery. In: Rubinstein M.H. (Ed). Physiological Pharmaceutics: Biological Barriers to Drug (1989), Absorption Ellis Horwood, Chichester 47-70
46. Woodnutt G., and Berry V. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43 (1999) 29-34
47. Woodnutt G., and Berry V. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrobial. Agents Chemother. 43 (1999) 35-40